Overview and History of NOLVAMED 20 (Tamoxifen
citrate)
NOLVAMED 20 (Tamoxifen citrate) belongs to a class of drugs known as selective Estrogen
receptor modulators (called SERMs for short). Selective Estrogen receptor modulators
belong to an even broader category of drugs known as anti-estrogens. The other subcategory
of drug under the anti-estrogens category is known as aromatase inhibitors (AIs),
such as AROMAMED 25 (Exemestane) and ARIMIMED 1 (Anastrozole).
AIs and SERMs make up anti-estrogens, also
known as Estrogen antagonists or Estrogen blockers. Aromatase inhibitors are very different from SERMs in their action and how
they deal with the issues of Estrogen control. There is a misconception among the anabolic steroid using community that SERMs,
such as NOLVAMED 20 (Tamoxifen citrate) and CLOMIMED 50 (Clomiphene citrate), serve to lower estrogen levels. That is not true.
SERMs serve to block the action of Estrogen at the receptor sites in breast tissue
by occupying the receptor sites in place of Estrogen so that Estrogen itself cannot
exert its effects there through receptor site binding. On the contrary, SERMs will also act as Estrogens at receptor
sites at other cells in other areas of the body (for example the liver, like NOLVAMED
20 (Tamoxifen citrate). SERMs do not lower circulating levels of Estrogen in blood plasma.
Aromatase inhibitors do this by eliminating the production of Estrogen through binding
to and disabling the aromatase enzyme, which is the enzyme responsible for the conversion
(or aromatization) of androgens into Estrogen.
NOLVAMED 20 (Tamoxifen citrate) is specifically a non-steroidal SERM which is part of
the triphenylethylene family of compounds that exhibits both Estrogen agonist and
Estrogen antagonistic effects on the body. Although NOLVAMED 20 (Tamoxifen
citrate) might block the effect of Estrogen at
the cellular level in certain tissues, it can enhance Estrogenic effects in other
areas of the body. These effects can be both: positive and negative. NOLVAMED
20 (Tamoxifen citrate) exhibits Estrogenic effects
in the liver, which is a positive effect, as it results in a positive change in
cholesterol profiles. The area of concern during the usage of NOLVAMED 20
(Tamoxifen citrate) is breast tissue, where the drug acts
as a very strong anti-Estrogen. This is where
it is utilized in the medical field,
as a first-line treatment in Estrogen-responsive female breast cancer patients.
NOLVAMED 20 (Tamoxifen citrate) is even
utilized in females that do not possess breast cancer but are known as being in
a high-risk category (due to hereditary genetics or otherwise) as a preventative
measure.
NOLVAMED 20 (Tamoxifen citrate) possesses other attractive effects, such as its ability
to increase circulating levels of endogenous gonadotropins Luteinizing Hormone (LH)
and Follicle Stimulating Hormone (FSH), and through this, increasing the endogenous
production of Testosterone. This is a great example of the mixed Estrogen antagonistic
and agonistic properties of NOLVAMED 20 (Tamoxifen citrate), where it works to block the ability for Estrogen to
bind to receptors at the hypothalamus. Such actions result in the manipulation of
the negative feedback loop of the HPTA (Hypothalamic Pituitary Testicular Axis),
and in the increased output of gonadotropins (the hormones that signal the testes
to begin or increase the output of Testosterone production). Because of this reason
NOLVAMED 20 (Tamoxifen citrate) is considered
an essential component of a PCT (Post Cycle Therapy) cycle to restore the function of endogenous Testosterone production.
Tamoxifen citrate was developed by ICI in 1962 and shortly afterward was released onto
the prescription drug market in the United States.
The very first application of this compound in medicine was the treatment of female
infertility. Later, after various clinical testing, NOLVAMED 20
(Tamoxifen citrate) was found to be highly effective
in the treatment of breast cancer patients. Tamoxifen citrate has spread internationally. Thousands of different brands
and generics of it have been created.
Chemical Characteristics
of NOLVAMED 20 (Tamoxifen citrate)
NOLVAMED 20 (Tamoxifen citrate) is a non-steroidal
selective Estrogen receptor modulator (SERM) that possesses both mixed agonistic
and antagonistic properties concerning Estrogen in different areas of the body.
NOLVAMED 20 (Tamoxifen citrate) is part
of the family of compounds known as triphenylethylene
compounds. CLOMIMED 50 (Clomiphene citrate) is also a member of this family and a very closely related
compound to NOLVAMED 20 (Tamoxifen citrate).
Properties of NOLVAMED 20 (Tamoxifen citrate)
Being a SERM, NOLVAMED 20 (Tamoxifen citrate) does not reduce circulating Estrogen levels in the body
but instead serves to occupy the receptor sites in breast tissue so that Estrogen
itself cannot bind to these receptors due to NOLVAMED 20 (Tamoxifen citrate)
stronger binding strength to it. NOLVAMED
20 (Tamoxifen citrate) acts as a ‘fake’ Estrogen
that acts as a placeholder at the receptor sites in breast tissue. As a result,
Estrogen cannot activate gene transcription in the cells there to formulate gynecomastia,
and any existing Estrogen that has already bound to receptor sites will essentially
be ‘forced’ out of the receptor sites by NOLVAMED 20 (Tamoxifen citrate)
which then occupies the receptor site instead.
This quality is perfect for anabolic steroid users that wish to eliminate and reverse
formulating gynecomastia in its early stages, as well as for those users which are
very sensitive to the gynecomastia side effect of rising Estrogen levels that might
wish to use NOLVAMED 20 (Tamoxifen citrate) as a preventative measure. This is the primary function of NOLVAMED
20 (Tamoxifen citrate) and is the main desired effect that anabolic steroid using bodybuilders
and athletes utilize it for.
NOLVAMED 20 (Tamoxifen citrate) will not serve to block
or reduce any other Estrogenic side effects, as it serves only to block Estrogenic
activity at the breast tissue area (when major Estrogenic side effects are concerned).
The same like any other SERMs, NOLVAMED 20 (Tamoxifen citrate) does not serve to
reduce bloating, water retention, rising blood pressure (as a result of water retention), or acne formation – these are all side
effects resultant from increasing blood plasma Estrogen levels.
NOLVAMED 20 (Tamoxifen citrate) Side Effects
NOLVAMED 20 (Tamoxifen citrate) is a compound that is tolerated quite well by the majority
of users. Like with any other compound, there are some potential side effects to
be aware of. Because of the difference in androgen and Estrogen receptor proliferation
among cells in the male and female bodies, NOLVAMED 20
(Tamoxifen citrate) can generate quite different
effects depending on the gender of the user. This is the reason why there are many
negative experiences with NOLVAMED 20 (Tamoxifen citrate) side effects among female users. Anyway, this is a different story in comparison to its
use among bodybuilders and athletes using NOLVAMED 20 (Tamoxifen citrate)
as an ancillary compound surrounding their anabolic
steroid use.
The official prescription documentation
for NOLVAMED 20
(Tamoxifen citrate) side effects when it is used
as a female breast cancer treatment drug includes hot flashes, vaginal itching,
upset stomach, headaches, dizziness, bone and joint pains,
and edema. Less common side effects may include cholesterol changes, altered white
blood cell count, altered platelet count, skin rashes, endometrial changes, deep
vein thrombosis, and pulmonary embolism. The mentioned NOLVAMED 20 (Tamoxifen
citrate) side effects are practically a non-concern
for male users, as the overwhelming majority of said side
effects are reportedly seldom experienced among men users.
Dosages and Administration of NOLVAMED 20
(Tamoxifen citrate)
In the medical field, NOLVAMED
20 (Tamoxifen citrate) is used as a medication
in the treatment of 6 different types of female breast cancer. The prescription dosing and administration of NOLVAMED
20 (Tamoxifen citrate) in these cases call for
10 – 20mg taken twice per day, in the morning and evening respectively.
Within the bodybuilding and performance
enhancement world, NOLVAMED 20 (Tamoxifen citrate) is primarily used as an ancillary aid to combating,
reducing, and/or preventing the development of Gynecomastia. This usually happens
when a particularly moderate or aromatizable anabolic steroid is utilized in a cycle.
Dosing of NOLVAMED 20 (Tamoxifen citrate) in this case is approximately 10 – 30mg per day. The common dosing tends to
be 20mg per day of NOLVAMED 20 (Tamoxifen citrate). That must
be noted, that higher dosages of NOLVAMED 20 (Tamoxifen citrate), greater than 20 – 40mg per
day, does not produce any greater or faster effect on reducing or preventing gynecomastia.
The other purpose for NOLVAMED 20 (Tamoxifen citrate) use among bodybuilders and athletes is its ability to stimulate
and increase the male production of endogenous Testosterone, as many studies have
shown. It does so by acting on the pituitary and hypothalamus gland in the brain
and signaling an increase in production of FSH (Follicle Stimulating Hormone) and
LH (Luteinizing Hormone), which then signals the testes to produce Testosterone.
NOLVAMED 20 (Tamoxifen citrate) is usually
administered during PCT, which is immediately after the anabolic steroid cycle is
complete and all anabolic steroids are clear from the
individual’s system. The dosage is 20 –
40mg per day, the cycle length of approximately 4 – 6 weeks. Studies have shown that venturing higher than 20 –
40mg per day does not generate any significantly greater amount of Testosterone
production.
NOLVAMED 20 (Tamoxifen citrate) is usually included with the administration of at least
one or two other Testosterone stimulating compounds during PCT (such as an aromatase
inhibitor, usually AROMAMED 25 (Exemestane), and/or HCG) to enhance its effects on promoting proper
HPTA function following the conclusion of a cycle. The utilization of NOLVAMED 20 (Tamoxifen citrate) during
a cycle will not counter-act the Testosterone suppression of anabolic steroid use
and will not keep endogenous Testosterone production going amidst the use of suppressive
compounds. It is therefore not recommended to do that, as it would be useless.
NOLVAMED 20 (Tamoxifen citrate) possesses an extremely
long half-life for an oral compound, approximately 5 – 7 days. Some studies even
demonstrated a longer half-life of 14 days. Because of this, there is no requirement
to split dosages throughout the day. It is safe to consume NOLVAMED 20 (Tamoxifen
citrate) together with food or on
an empty stomach.
Chemical info / Information
Tamoxifen Citrate (AKA Nolvadex)
Chemical Name: (Z)-2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine
Molecular Weight: 371.515 g/mol or 563.638 g/mol (citrate salt)
Formula: C26H29NO
Original Manufacturer: ICI
Elimination half-life: 5 – 7 days (some reports as long as 14 days)
Detection Time: 2 months
Anabolic Rating: N/A
Androgenic Rating: N/A
Related Products
